A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation

BACKGROUND: Regulatory concern about potential QT-interval prolongation by serotonin-receptor antagonist antiemetics prompted product-label changes. The first-generation serotonin-receptor antagonist granisetron is available in oral (PO), intravenous (IV), and transdermal formulations. APF530 is a f...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Mason, Jay W, Moon, Thomas E, O’Boyle, Erin, Dietz, Albert
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2014
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3970917/
https://ncbi.nlm.nih.gov/pubmed/24741326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S58071
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi